Canaccord Genuity Maintains a Hold Rating on Teva Pharma

By George MacDonald

In a report released yesterday, Corey Davis from Canaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), with a price target of $63. The company’s shares opened today at $62.30, close to its 52-week high of $64.08.

Teva Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $70.

Based on Teva Pharma`s latest earnings report from December 31, the company posted quarterly revenue of $5.17B and quarterly net profit of $687M. In comparison, last year the company earned revenue of $5.43B and had a net profit of $380M.

According to TipRanks.com, Davis is a top 100 analyst with an average return of 36.0% and a 74.2% success rate. Davis covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Infotek Pharmaceuticals, and Pacira Pharmaceuticals.

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.